
Health Canada Approves IMFINZI® for Adult Patients with Limited-Stage Small Cell Lung Cancer
Health Canada has granted a Notice of Compliance (NOC) for AstraZeneca Canada’s IMFINZI® (durvalumab), as monotherapy, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following …